Publikationen in Zusammenarbeit mit Forschern von Hospital Universitario de Salamanca (76)

2024

  1. Cáncer de mama

    Oncología clínica (Arán), pp. 203-226

  2. Exercise in cancer patients: assistance levels and referral pathways—a position statement from the Spanish Society of Medical Oncology

    Clinical and Translational Oncology

  3. Late recurrence of lobular breast carcinoma presented as gastric metastasis

    Revista espanola de enfermedades digestivas, Vol. 116, Núm. 8, pp. 455-456

  4. PIK3CA mutational status in tissue and plasma as a prognostic biomarker in HR+/HER2− breast cancer

    Cancer Medicine, Vol. 13, Núm. 17

  5. Real-world clinical scenarios during introduction of trastuzumab biosimilar for HER2-positive breast cancer in the European Union

    Future oncology (London, England), Vol. 20, Núm. 13, pp. 821-832

  6. SEOM 2023 clinical guidelines

    Clinical and Translational Oncology

  7. Safety profile of trastuzumab deruxtecan in advanced breast cancer: Expert opinion on adverse event management

    Clinical and Translational Oncology, Vol. 26, Núm. 7, pp. 1539-1548

  8. Tratamiento Sistémico del Cáncer (I): Quimioterapia

    Oncología clínica (Arán), pp. 73-87

  9. Tratamiento Sistémico del Cáncer (II): hormonoterapia

    Oncología clínica (Arán), pp. 89-99

  10. Tratamiento Sistémico del Cáncer (III): inmunoterapia y terapias biológicas

    Oncología clínica (Arán), pp. 101-116

  11. Urgencias en oncología

    Oncología clínica (Arán), pp. 129-145

2023

  1. Impact of the 21-Gene Assay in Patients with High-Clinical Risk ER-Positive and HER2-Negative Early Breast Cancer: Results of the KARMA Dx Study

    Cancers, Vol. 15, Núm. 5

  2. Intermediate Molecular Phenotypes to Identify Genetic Markers of Anthracycline-Induced Cardiotoxicity Risk

    Cells, Vol. 12, Núm. 15

2022

  1. Safety and efficacy of ribociclib plus letrozole in patients with HR+, HER2– advanced breast cancer: Results from the Spanish sub-population of the phase 3b CompLEEment-1 trial

    Breast, Vol. 66, pp. 77-84

2021

  1. Health-related quality of life with palbociclib plus endocrine therapy versus capecitabine in postmenopausal patients with hormone receptor–positive metastatic breast cancer: Patient-reported outcomes in the PEARL study

    European Journal of Cancer, Vol. 156, pp. 70-82

  2. Value of skin tests for managing allergic hypersensitivity reactions to platinum compounds

    International Journal of Clinical Pharmacy, Vol. 43, Núm. 4, pp. 1123-1127

2020

  1. A retrospective, multicenter study of the efficacy of lapatinib plus trastuzumab in HER2-positive metastatic breast cancer patients previously treated with trastuzumab, lapatinib, or both: the Trastyvere study

    Clinical and Translational Oncology, Vol. 22, Núm. 3, pp. 420-428

  2. Palbociclib combined with endocrine therapy in heavily pretreated HR+/HER2- advanced breast cancer patients: Results from the compassionate use program in Spain (PALBOCOMP)

    Breast, Vol. 54, pp. 286-292

  3. Phase III study to evaluate patient’s preference of subcutaneous versus intravenous trastuzumab in HER2-positive metastatic breast cancer patients: Results from the ChangHER study (GEICAM/2012-07)

    European Journal of Cancer Care, Vol. 29, Núm. 4

  4. Stromal SNAI2 is required for ERBB2 breast cancer progression

    Cancer Research, Vol. 80, Núm. 23, pp. 5216-5230